| Revista: | Anais brasileiros de dermatologia |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000410497 |
| ISSN: | 0365-0596 |
| Autores: | Santos, Julia Rocha Silva1 Vendramini, Damia Leal1 Nery, Jose Augusto da Costa1 Avelleira, Joao Carlos Regazzi1 |
| Instituciones: | 1Santa Casa de Misericordia do Rio de Janeiro, Instituto de Dermatologia Professor Rubem David Azulay, Rio de Janeiro. Brasil |
| Año: | 2017 |
| Periodo: | Jul-Ago |
| Volumen: | 92 |
| Número: | 4 |
| Paginación: | 578-580 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Caso clínico, descriptivo |
| Resumen en inglés | One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature. A good response was found after an assay with infliximab and etanercept. This study reports on a patient with lepromatous leprosy and recurrent reaction, controlled by using etanercept and a 10-month follow-up, with the interruption of thalidomide and the maintenance of prednisone at 10 mg/day |
| Disciplinas: | Medicina |
| Palabras clave: | Dermatología, Farmacología, Lepra, Eritema nodoso, Factor de necrosis tumoral, Etanercept, Prednisona |
| Keyword: | Medicine, Dermatology, Pharmacology, Leprosy, Erythema nodosum, Tumor necrosis factor, Etanercept, Prednisone |
| Texto completo: | Texto completo (Ver HTML) |
